iShares China Large-Cap ETF (FXI) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $41.7552W High
- $31.5952W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares China Large-Cap ETF (FXI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares China Large-Cap ETF has traded between a low of $31.59 and a high of $41.75, highlighting its annual price range. Buy and sell iShares China Large-Cap ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Most Recent News
US Department of War suspends costly CMMC Phase II cybersecurity rules for small defense contractors.
The U.S. Department of War has suspended the Cybersecurity Maturity Model Certification (CMMC) Phase II requirements originally set for November 2026, following concerns from small defense contractors about high compliance costs and bureaucratic burd...

AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.